Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial

20252 citationsJournal Articlehybrid Open Access

Authors

Amy K. Dickey · Harvard University

Herbert L. Bonkovsky · Atrium Health Wake Forest Baptist

Manisha Balwani · Icahn School of Medicine at Mount Sinai

Karl E. Anderson · The University of Texas Medical Branch at Galveston

Cynthia Levy · University of Miami

Manish Thapar · Temple University Hospital

Bruce Wang

Abstract

Bitopertin significantly reduced protoporphyrin-IX levels, showed improved measures of sunlight tolerance, and had a favorable safety profile in patients with erythropoietic protoporphyria.

Topics & Keywords

Porphyrin Metabolism and Disorders Photodynamic Therapy Research Studies Neonatal Health and Biochemistry

Publication Details

Published in: Journal of the American Academy of Dermatology

Volume 94, Issue 4, pp. 1167-1176

DOI: 10.1016/j.jaad.2025.12.024

Field-Weighted Citation Impact: 1.63

Command Palette

Bitopertin shows efficacy in patients with erythropoietic protoporphyria: Results from the randomized, double-blind, placebo-controlled AURORA trial

Authors

Abstract

Topics & Keywords

Publication Details